Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis.
Dagogo-Jack I, Kiedrowski LA, Heist RS, Lin JJ, Meador CB, Krueger EA, Do A, Peterson J, Sequist LV, Gainor JF, Lennerz JK, Digumarthy SR. Dagogo-Jack I, et al. Among authors: lennerz jk. JTO Clin Res Rep. 2023 Jun 1;4(8):100534. doi: 10.1016/j.jtocrr.2023.100534. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37533439 Free PMC article.
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Medford AJ, Oshry L, Boyraz B, Kiedrowski L, Menshikova S, Butusova A, Dai CS, Gogakos T, Keenan JC, Occhiogrosso RH, Ryan P, Lennerz JK, Spring LM, Moy B, Ellisen LW, Bardia A. Medford AJ, et al. Among authors: lennerz jk. Ther Adv Med Oncol. 2023 Jan 30;15:17588359231152844. doi: 10.1177/17588359231152844. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36743521 Free PMC article.
Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer.
Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, Barth JL, Dubash T, Chirn B, Parida L, Sequist LV, Lennerz JK, Mino-Kenudson M, Maheswaran S, Naxerova K, Getz G, Haber DA. Burr R, et al. Among authors: lennerz jk. medRxiv [Preprint]. 2023 Sep 29:2023.09.28.23296274. doi: 10.1101/2023.09.28.23296274. medRxiv. 2023. Update in: Nat Cancer. 2024 Nov;5(11):1681-1696. doi: 10.1038/s43018-024-00840-y PMID: 37808694 Free PMC article. Updated. Preprint.
A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma.
Goyal L, DiToro D, Facchinetti F, Martin EE, Peng P, Baiev I, Iyer R, Maurer J, Reyes S, Zhang K, Majeed U, Berchuck JE, Chen CT, Walmsley C, Pinto C, Vasseur D, Gordan JD, Mody K, Borad M, Karasic T, Damjanov N, Danysh BP, Wehrenberg-Klee E, Kambadakone AR, Saha SK, Hoffman ID, Nelson KJ, Iyer S, Qiang X, Sun C, Wang H, Li L, Javle M, Lin B, Harris W, Zhu AX, Cleary JM, Flaherty KT, Harris T, Shroff RT, Leshchiner I, Parida L, Kelley RK, Fan J, Stone JR, Uboha NV, Hirai H, Sootome H, Wu F, Bensen DC, Hollebecque A, Friboulet L, Lennerz JK, Getz G, Juric D. Goyal L, et al. Among authors: lennerz jk. Ann Oncol. 2024 Dec 18:S0923-7534(24)04990-1. doi: 10.1016/j.annonc.2024.12.011. Online ahead of print. Ann Oncol. 2024. PMID: 39706336 Free article.
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma.
Singh H, Lowder KE, Kapner K, Kelly RJ, Zheng H, McCleary NJ, Abrams TA, Chan JA, Regan EM, Klempner SJ, Hannigan AM, Remland J, Brais LK, Andrews E, Yurgelun M, Cleary JM, Rubinson DA, Ritterhouse LL, Maron G, Aguirre AJ, Meyerhardt JA, Gardecki E, Lennerz JK, Wolpin BM, Enzinger PC. Singh H, et al. Among authors: lennerz jk. Nat Commun. 2024 Aug 9;15(1):6833. doi: 10.1038/s41467-024-51271-3. Nat Commun. 2024. PMID: 39122726 Free PMC article. Clinical Trial.
Prognostic biomarkers for survival in mucosal melanoma.
Thierauf JC, Kaluziak ST, Codd E, Dybel SN, Jobbagy S, Purohit R, Farahani AA, Dedeilia A, Naranbhai V, Hoang MP, Fisch AS, Ritterhouse L, Boland GM, Lennerz JK, Iafrate AJ. Thierauf JC, et al. Among authors: lennerz jk. Pigment Cell Melanoma Res. 2023 Sep;36(5):378-387. doi: 10.1111/pcmr.13104. Epub 2023 Jun 30. Pigment Cell Melanoma Res. 2023. PMID: 37390098
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.
Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C, Roberts LR, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Kelley RK, Javle MM, Goyal L. Spencer K, et al. Among authors: lennerz jk. J Natl Cancer Inst. 2023 Jul 6;115(7):870-880. doi: 10.1093/jnci/djad046. J Natl Cancer Inst. 2023. PMID: 37040087 Free PMC article.
Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.
Kaj-Carbaidwala B, Fevery J, Adler DG, Bergquist A, de Ridder L, Deneau M, Gower-Rousseau C, Chapman RW, Lynch KD, Stedman CAM, Wilson DC, Shah U, Goyal L, Winter HS, Lennerz JK. Kaj-Carbaidwala B, et al. Among authors: lennerz jk. J Pediatr Gastroenterol Nutr. 2024 Dec 20. doi: 10.1002/jpn3.12443. Online ahead of print. J Pediatr Gastroenterol Nutr. 2024. PMID: 39704261
242 results